Ceptaris therapeutics inc
WebTo report SUSPECTED ADVERSE REACTIONS, contact Ceptaris Therapeutics, Inc. at 1‐855‐4‐VALCHLOR (1‐855‐482‐5245) or FDA at 1‐800‐FDA‐1088 or … WebCompany Name Country [desc] Neurelis, Inc. USA: Archer Pharmaceuticals, Inc. USA: NeuroPhage Pharmaceuticals, Inc. USA: Argos Therapeutics, Inc. USA: Avanir ...
Ceptaris therapeutics inc
Did you know?
WebCeptaris Therapeutics Inc. Sale of privately held, specialty pharmaceutical company with FDA-approved orphan drug for early stage mycosis fungoides. View Press Release. Ceptaris developed VALCHLOR™, a proprietary gel formulation of mechlorethamine for the treatment of early stage (IA and IB) mycosis fungoides, a type of cutaneous T-cell ... WebCeptaris Therapeutics, Inc. Developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of …
WebSep 20, 2013 · Actelion Ltd. ( ALIOF) completed the acquisition of privately-held Ceptaris Therapeutics. The acquisition closed on the heels of Ceptaris’ drug Valchlor gaining U.S. Food and Drug Administration ... WebCEPTARIS THERAPEUTICS, INC: Street Address 1 Street Address 2; 101 LINDENWOOD DRIVE: SUITE 400: City State/Province/Country ZIP/PostalCode Phone Number of …
WebCeptaris Therapeutics artrix 2024-09-09T20:49:05-07:00. Project Description. Project Details. Categories: North America Biopharm Exited Region Industry ... Visirna Therapeutics Inc. Gallery Visirna … WebMar 6, 2024 · Previously, he held position of Chief Medical Officer at Onspira Therapeutics, Lycera, and Ceptaris Therapeutics, Inc., where he led clinical programs from IND Phase I trials to regulatory ...
WebLisa Wittmer, Ph.D. has more than 20 years’ experience and a demonstrated track record in leading development from early stages through to licensing, registration and commercialization of new therapeutics. Throughout her career, Dr. Wittmer has held executive and senior management positions in research & development, product strategy ...
WebAug 1, 2013 · Stephen Tullman, President and CEO, Ceptaris Therapeutics, Inc. Related news: UPDATE 1-Actelion buys U.S.-based specialty drugmaker Ceptaris (Reuters) Reference links: Actelion press release. handballschuhe asics herrenWebJul 31, 2013 · VALCHLOR has a PDUFA date of 27 August 2013. Under the terms of the Merger Agreement, Actelion paid to Ceptaris USD 25 million upon signing and will pay to Ceptaris' shareholders USD 225 million ... buses from bognor regisWebRepresented Ceptaris Therapeutics, Inc. in connection with $15 million venture debt financing. Represented Ception Therapeutics in a $12 million venture debt financing. … buses from bodmin to liskeardWebManufactured for: Ceptaris Therapeutics, Inc., Malvern, PA 19355 © 2013 Ceptaris Therapeutics, Inc. All rights reserved. For more information, go to … buses from bognor regis to brightonWebCeptaris Therapeutics, Inc. was subsequently acquired by Swiss based Actelion Ltd for over $250 MM and additional payments. Nonclinical … handball scheme of work year 9WebCeptaris Therapeutics, Inc is a corporation in Malvern, Pennsylvania. The employer identification number (EIN) for Ceptaris Therapeutics, Inc is 020555180. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC. buses from bolton to londonWebCeptaris Therapeutics, Inc / Malvern Strategic design of nonclinical RD studies of nornicotine for smoking cessation and S-(+)-norketamine for neuropathic pain, saving … hand ball rule in football